Repare Therapeutics’ (RPTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research note released on Friday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th.

Repare Therapeutics Price Performance

Shares of RPTX traded up $0.08 during trading hours on Friday, hitting $3.67. The stock had a trading volume of 7,573 shares, compared to its average volume of 161,483. The firm has a 50 day simple moving average of $3.35 and a 200-day simple moving average of $3.40. Repare Therapeutics has a 1-year low of $2.71 and a 1-year high of $8.49. The firm has a market capitalization of $155.79 million, a P/E ratio of -1.80 and a beta of 0.72.

Hedge Funds Weigh In On Repare Therapeutics

A number of large investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its position in shares of Repare Therapeutics by 212.1% in the second quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock worth $1,373,000 after buying an additional 284,036 shares in the last quarter. Blue Owl Capital Holdings LP grew its holdings in shares of Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock worth $11,129,000 after purchasing an additional 250,000 shares in the last quarter. Squarepoint Ops LLC raised its stake in Repare Therapeutics by 428.4% in the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock valued at $472,000 after purchasing an additional 115,916 shares in the last quarter. Renaissance Technologies LLC grew its stake in Repare Therapeutics by 30.7% in the 2nd quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock worth $1,514,000 after buying an additional 107,700 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Repare Therapeutics in the 2nd quarter worth $273,000. 85.09% of the stock is currently owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.